Optimizing Organ-Preservation Strategies Through Chemotherapy-Based Selection in Esophageal Squamous Cell Carcinoma: Results From the CROC Multi-Institutional Phase 2 Clinical Trial
-
Published:2024-07
Issue:
Volume:
Page:
-
ISSN:0360-3016
-
Container-title:International Journal of Radiation Oncology*Biology*Physics
-
language:en
-
Short-container-title:International Journal of Radiation Oncology*Biology*Physics
Author:
Katada ChikatoshiORCID, Yokoyama Tetsuji, Watanabe Akinori, Hara Hiroki, Yoshii Takako, Fujii Hirofumi, Yamaguchi Hironori, Nakajima Takako Eguchi, Izawa Naoki, Ando Takayuki, Nomura Motoo, Kojima Takashi, Yamashita Keishi, Kawakami Shogo, Ishiyama Hiromichi, Inoue Yusuke, Sakamoto Yasutoshi, Sasaki Hiroki, Ishikawa Hideki, Hosokawa Ayumu, Hamamoto Yasuo, Muto Manabu, Tahara Makoto, Koizumi Wasaburo
Reference34 articles.
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Esophageal and Esophagogastric Junction Cancers Version 2. 2023. © National Comprehensive Cancer Network, Inc. 2023. Accessed December 3, 2023. https://www.NCCN.org 2. Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part1;Kitagawa;Esophagus,2023 3. Phase II feasibility study of preoperative chemotherapy with docetaxel, cisplatin, and fluorouracil for esophageal squamous cell carcinoma;Hara;Cancer Sci,2013 4. Phase II study of chemoselection with docetaxel plus cisplatin and 5–fluorouracil induction chemotherapy and subsequent conversion surgery for locally advanced unresectable oesophageal cancer;Yokota;Br J Cancer,2016 5. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomised, controlled, open-label, phase 3 trial;Kato;Lancet,2024
|
|